Urothelial Carcinoma in Bladder Diverticula
Standard
Urothelial Carcinoma in Bladder Diverticula : A Multicenter Analysis of Characteristics and Clinical Outcomes. / Voskuilen, Charlotte S; Seiler, Roland; Rink, Michael; Poyet, Cédric; Noon, Aidan P; Roghmann, Florian; Necchi, Andrea; Aziz, Atiqullah; Lavollé, Alexandre; Young, Matthew J; Marks, Phillip; Saba, Karim; van Rhijn, Bas W G; Fransen van de Putte, Elisabeth E; Ablat, Jason; Black, Peter C; Sosnowski, Roman; Dobruch, Jakub; Kumar, Pardeep; Jallad, Samer; Catto, James W F; Xylinas, Evanguelos; Hendricksen, Kees; Young Academic Urologists’ Working Group on Urothelial Carcinoma of the European Association of Urology.
in: EUR UROL FOCUS, 2018.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Urothelial Carcinoma in Bladder Diverticula
T2 - A Multicenter Analysis of Characteristics and Clinical Outcomes
AU - Voskuilen, Charlotte S
AU - Seiler, Roland
AU - Rink, Michael
AU - Poyet, Cédric
AU - Noon, Aidan P
AU - Roghmann, Florian
AU - Necchi, Andrea
AU - Aziz, Atiqullah
AU - Lavollé, Alexandre
AU - Young, Matthew J
AU - Marks, Phillip
AU - Saba, Karim
AU - van Rhijn, Bas W G
AU - Fransen van de Putte, Elisabeth E
AU - Ablat, Jason
AU - Black, Peter C
AU - Sosnowski, Roman
AU - Dobruch, Jakub
AU - Kumar, Pardeep
AU - Jallad, Samer
AU - Catto, James W F
AU - Xylinas, Evanguelos
AU - Hendricksen, Kees
AU - Young Academic Urologists’ Working Group on Urothelial Carcinoma of the European Association of Urology
N1 - Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.
PY - 2018
Y1 - 2018
N2 - BACKGROUND: Urothelial carcinoma arising in a bladder diverticulum (UCBD) is uncommon, and data on treatment and outcome are sparse.OBJECTIVE: To analyze clinicopathological characteristics of UCBD and to compare outcome after radical cystectomy (RC) and partial cystectomy (PC).DESIGN, SETTING, AND PARTICIPANTS: Data of 115 UCBD patients treated with RC (n=81) or PC (n=34) between 2000 and 2016 were collected from 11 institutional databases and were analyzed retrospectively. Median follow-up was 5.0yr (95% confidence interval [CI]: 4.0-6.2).OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Upstaging of tumor stage at diagnostic transurethral resection (TUR) to the RC/PC specimen was investigated. Overall survival (OS) and metastasis-free survival (MFS) after RC and PC were analyzed using Kaplan-Meier estimates, and compared using the log-rank test. Intravesical recurrences after PC were reported. A multivariable Cox proportional-hazard model was used to identify factors associated with OS.RESULTS AND LIMITATIONS: There were no statistically significant differences in clinicopathological characteristics between RC and PC groups. Fifty-five percent of patients with cTa/is/1 at diagnostic TUR had ≥pT2 tumors at RC/PC. Five-year OS and MFS were, respectively, 62% and 66% for RC and 66% and 55% for PC (p=0.9 and p=0.6). Intravesical tumor recurrence was seen in six of 34 (18%) PC patients. In multivariable analysis, positive surgical margins and extravesical disease (≥pT2) were associated with worse OS, whereas treatment modality was not (RC: reference; PC: hazard ratio 0.94, [95% CI: 0.47-1.90], p=0.9).CONCLUSIONS: Upstaging of UCBD was frequent, indicating an inaccuracy in clinical staging. We found no differences in OS or MFS between PC and RC groups; therefore, PC may represent a feasible surgical alternative to RC in selected UCBD patients.PATIENT SUMMARY: In this report, we looked at the treatment of urothelial carcinoma arising in a bladder diverticulum (UCBD). We found that bladder-sparing treatment by partial cystectomy may be an alternative to radical cystectomy in carefully selected UCBD patients.
AB - BACKGROUND: Urothelial carcinoma arising in a bladder diverticulum (UCBD) is uncommon, and data on treatment and outcome are sparse.OBJECTIVE: To analyze clinicopathological characteristics of UCBD and to compare outcome after radical cystectomy (RC) and partial cystectomy (PC).DESIGN, SETTING, AND PARTICIPANTS: Data of 115 UCBD patients treated with RC (n=81) or PC (n=34) between 2000 and 2016 were collected from 11 institutional databases and were analyzed retrospectively. Median follow-up was 5.0yr (95% confidence interval [CI]: 4.0-6.2).OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Upstaging of tumor stage at diagnostic transurethral resection (TUR) to the RC/PC specimen was investigated. Overall survival (OS) and metastasis-free survival (MFS) after RC and PC were analyzed using Kaplan-Meier estimates, and compared using the log-rank test. Intravesical recurrences after PC were reported. A multivariable Cox proportional-hazard model was used to identify factors associated with OS.RESULTS AND LIMITATIONS: There were no statistically significant differences in clinicopathological characteristics between RC and PC groups. Fifty-five percent of patients with cTa/is/1 at diagnostic TUR had ≥pT2 tumors at RC/PC. Five-year OS and MFS were, respectively, 62% and 66% for RC and 66% and 55% for PC (p=0.9 and p=0.6). Intravesical tumor recurrence was seen in six of 34 (18%) PC patients. In multivariable analysis, positive surgical margins and extravesical disease (≥pT2) were associated with worse OS, whereas treatment modality was not (RC: reference; PC: hazard ratio 0.94, [95% CI: 0.47-1.90], p=0.9).CONCLUSIONS: Upstaging of UCBD was frequent, indicating an inaccuracy in clinical staging. We found no differences in OS or MFS between PC and RC groups; therefore, PC may represent a feasible surgical alternative to RC in selected UCBD patients.PATIENT SUMMARY: In this report, we looked at the treatment of urothelial carcinoma arising in a bladder diverticulum (UCBD). We found that bladder-sparing treatment by partial cystectomy may be an alternative to radical cystectomy in carefully selected UCBD patients.
KW - Journal Article
U2 - 10.1016/j.euf.2018.12.002
DO - 10.1016/j.euf.2018.12.002
M3 - SCORING: Journal article
C2 - 30559065
JO - EUR UROL FOCUS
JF - EUR UROL FOCUS
SN - 2405-4569
ER -